ClinicalTrials.gg
CompletedNCT02019277SAPPHIREUpdated Sep 13, 2018Results posted

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

A Phase 3 interventional study of Docetaxel and Nab-paclitaxel in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 13 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.

Enrollment
210th of 366
50 · median 61
Started
2013
with 25 others
Phase 3
60 of 374
3 open now
Registered
214th of 374
by date
Lead sponsor
31 of 374
Hoffmann-La Roche

Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 210th largest by enrollment of the 366 interventional ones that give a count, is one of 26 that started in 2013, is one of 60 in phase 3, and was the 214th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 374 studies testing trastuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This open-label, multicenter, Phase IIIb study will assess the safety, tolerability and efficacy of a combination therapy of intravenous (IV) pertuzumab (Perjeta), trastuzumab (Herceptin) SC, and taxane chemotherapy (docetaxel, paclitaxel or nab-paclitaxel) as first-line therapy in participants with HER2-positive metastatic breast cancer (mBC). All participants will be treated with 3-week cycles of pertuzumab IV (840 milligrams [mg] first dose; subsequent doses of 420 mg) and trastuzumab SC (600 milligrams [mg]). The taxane treatment regimen will be determined by the investigator. Participants will continue therapy until disease progression, unacceptable toxicity, or the participant withdraws consent, whichever occurs first.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -positive disease, with an immunohistochemistry score of 3+ or in situ hybridization (ISH)-positive on primary tumor or site
  • or cytologically confirmed adenocarcinoma of the breast with metastatic disease with at least one and/or non-measurable disease according to Version 1.1
  • (ECOG) performance status 0-2 for participants who will receive paclitaxel or nab-paclitaxel chemotherapy and ECOG 0-1 for participants who will receive docetaxel chemotherapy
  • of greater than or equal to (>=) 50 percent (%) measured by ECHO or MUGA scan before the first doses of pertuzumab and trastuzumab
  • Previous use of either or neoadjuvant anti-HER2 therapy is allowed
  • Hormonal therapy will be allowed as per institutional guidelines. Hormonal therapy cannot be administered in combination with taxane therapy

Exclusion criteria

Exclusion Criteria:

  • Previous systemic non-hormonal anticancer therapy for treatment of mBC
  • History of other cancers. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively-treated cancers who have been disease-free for at least 5 years are eligible. Participants with previous ductal carcinoma in situ (DCIS) of the breast are also eligible for the study
  • Pregnant or breastfeeding women. Positive serum pregnancy test in women of , premenopausal or less than 12 months of amenorrhea , within 7 days before the first dose of pertuzumab and trastuzumab
  • Current peripheral neuropathy of Grade 3 or greater (National Cancer Institute [NCI CTCAE] Version 4.0)
  • Radiographic evidence of central nervous system (CNS) as assessed by computed tomography (CT) or magnetic resonance imaging (MRI), unless they have been treated and have been stable for at least 3 months and do not require ongoing treatment
  • Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
  • Inadequate organ function
  • Serious cardiac illness or medical conditions that would preclude the use of trastuzumab
  • Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
  • Concurrent enrollment in another clinical study using an anti-cancer treatment, within 28 days before the first doses of trastuzumab and pertuzumab
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Trastuzumab SC, Pertuzumab, and Taxane

    Participants will receive pertuzumab, trastuzumab and a taxane (docetaxel, paclitaxel or nab-paclitaxel) once every 3 weeks (21-day cycles). Choice of taxane will be at the discretion of the investigator and administered per routine clinical practices and local prescribing instructions.

    Drug: Docetaxel · Drug: Nab-paclitaxel · Drug: Paclitaxel · Drug: Pertuzumab · Drug: Trastuzumab

Interventions

  • Dosing regimen to be determined by the investigator, routine clinical practices.

  • Dosing regimen to be determined by the investigator, routine clinical practices.

  • Dosing regimen to be determined by the investigator, routine clinical practices.

  • Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.

    Also known as: Perjeta

  • Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.

    Also known as: Herceptin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious AEs

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs and SAEs was reported. AEs included both SAEs and non-SAEs. The 95% confidence interval (CI) was computed using Clopper-Pearson method.

    Time frame: Baseline up to 28 days after last study drug administration (up to 36 months)

  2. Percentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of AEs were graded according to NCI CTCAE version 4.0 on a 5-point scale: Grade 1=Mild, intervention not indicated; Grade 2=Moderate, local or noninvasive intervention indicated; Grade 3=Severe or medically significant but not immediately life-threatening; Grade 4= Life-threatening consequences, urgent intervention indicated; and Grade 5=Death related to AE. Percentage of participants with AEs by maximum severity grades was reported.

    Time frame: Baseline up to 28 days after last study drug administration (up to 36 months)

  3. Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs leading to premature discontinuation of IMPs (pertuzumab and trastuzumab) was reported. AEs included both SAEs and non-SAEs. The 95% CI was computed using Clopper-Pearson method.

    Time frame: Baseline up to 28 days after last study drug administration (up to 36 months)

  4. Percentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA)

    NYHA functional classification includes: Class I (no limitation in physical activity; ordinary physical activity does not cause fatigue, breathlessness or palpitation), Class II (slight limitation of physical activity; ordinary physical activity results in fatigue, palpitation, breathlessness or angina pectoris), Class III (marked limitation of physical activity; less than ordinary activity will lead to symptomatically 'moderate' heart failure) and Class IV (inability to carry out any physical activity without discomfort; symptoms of congestive cardiac failure are present even at rest). Percentage of participants with AEs suspected to be of cardiac origin by maximum NYHA classification was reported.

    Time frame: Baseline up to 28 days after last study drug administration (up to 36 months)

  5. Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%

    LVEF was assessed using echocardiography (ECHO) or multiple-gated acquisition (MUGA) scans. Percentage of participants with LVEF below 50% at any time during the study was reported.

    Time frame: Baseline up to 28 days after last study drug administration (up to 36 months)

Secondary outcomes

  1. Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    BOR was defined as a confirmed CR or PR. All measurable lesions up to a maximum of 2 lesions per organ and 5 in total were identified as target lesions (TLs) and recorded at baseline. A sum of the diameters (longest for non-nodal lesions, short axis \[SA\] for nodal lesions) for all TLs was calculated as baseline sum of diameters (SD). All other lesions (or sites of disease) were identified as non-TLs and were recorded at baseline. CR was defined as the disappearance of all TLs and SA reduction to less than (\<) 10 millimeter (mm) for nodal TLs/ non-TLs. PR was defined as greater than or equal to (\>/=) 30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. The 95% CI was computed using Clopper-Pearson method.

    Time frame: Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)

  2. Percentage of Participants With PD (Assessed According to RECIST Version 1.1) or Death Due to Any Cause

    For TLs, PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD, taking as reference the smallest SD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

    Time frame: Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)

  3. Progression-free Survival (PFS) Assessed According to RECIST Version 1.1

    PFS was defined as the time from start of treatment until first documented PD or death from any cause, whichever occurred first. Participants without PD, death, or who were lost to follow-up at the time of analysis were censored at the date of the last tumor assessment when non-progression was documented or at the last date of follow-up, whichever was last. Participants without tumor assessment data after the baseline were censored at baseline unless death occurred before first scheduled tumor assessment. PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, and/or unequivocal progression of existing non-TLs, or appearance of 1 or more new lesions. Median PFS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

    Time frame: Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)

  4. Percentage of Participants Who Died Due to Any Cause

    Percentage of participants who died due to any cause during the study was reported.

    Time frame: Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)

  5. Overall Survival (OS)

    The OS was defined as the time from the start of treatment until death from any cause. Participants alive at the time of analysis and participants who were lost to follow-up were censored at their last clinical assessment date. Median OS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

    Time frame: Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)

  6. Event-free Survival (EFS) Assessed According to RECIST Version 1.1

    EFS was defined as the time from the start of treatment until the first documented initiation of non-protocol-specified treatment for metastatic breast cancer, PD, or death from any cause, whichever occurred first. Participants without treatment change, PD, death, or who were lost to follow-up at the time of analysis were censored at the date of the last tumor assessment when non-progression was documented or at the last date of follow-up, whichever was last. Participants without tumor assessment after baseline were censored at baseline unless death occurred before first scheduled tumor assessment. PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, and/or unequivocal progression of existing non-TLs, or appearance of 1 or more new lesions. Median EFS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

    Time frame: Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)

  7. Percentage of Participants Who Died During Receiving Second-Line of Treatment

    Percentage of participants who died from any cause during second-line of treatment was reported.

    Time frame: From start of second-line of treatment (any time from baseline up to 35 months) up to death due to any cause or study end (up to approximately 36 months)

  8. OS During Second-Line of Treatment

    The OS during second-line therapy was defined as the time from the start of second-line therapy (failure of first-line therapy) until death from any cause. Participants alive at the time of analysis and participants who were lost to follow-up were censored at their last clinical assessment date. Median OS during second-line therapy was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

    Time frame: From start of second-line of treatment (any time from baseline up to 35 months) up to death due to any cause or study end (up to approximately 36 months)

  9. Number of Participants Receiving Second-Line Treatment by Treatment Type

    Second-line anti-cancer treatment was initiated after disease progression on first-line therapy. Number of participants who started second-line of treatment by treatment type was reported. Participants who received combination treatment were counted for each treatment type.

    Time frame: Baseline up to approximately 35 months

07

Results

Posted Jul 23, 2018

Participant flow

Participant flow — Overall Study
MilestoneTrastuzumab, Pertuzumab, and Taxane
Started50
Completed38
Not completed12
Withdrew: Withdrawal by subject3
Withdrew: Death7
Withdrew: Did no cooperate1
Withdrew: Adverse event1

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs) and Serious AEs

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs and SAEs was reported. AEs included both SAEs and non-SAEs. The 95% confidence interval (CI) was computed using Clopper-Pearson method.

Time frame:
Baseline up to 28 days after last study drug administration (up to 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious AEs
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
AEs100.0 (92.9 to 100.0)
SAEs54.0 (39.3 to 68.2)
SecondaryPercentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

BOR was defined as a confirmed CR or PR. All measurable lesions up to a maximum of 2 lesions per organ and 5 in total were identified as target lesions (TLs) and recorded at baseline. A sum of the diameters (longest for non-nodal lesions, short axis \[SA\] for nodal lesions) for all TLs was calculated as baseline sum of diameters (SD). All other lesions (or sites of disease) were identified as non-TLs and were recorded at baseline. CR was defined as the disappearance of all TLs and SA reduction to less than (\<) 10 millimeter (mm) for nodal TLs/ non-TLs. PR was defined as greater than or equal to (\>/=) 30% decrease in SD of TLs, taking as reference the baseline SD. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. The 95% CI was computed using Clopper-Pearson method.

Time frame:
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.173.3 (58.1 to 85.4)
SecondaryPercentage of Participants With PD (Assessed According to RECIST Version 1.1) or Death Due to Any Cause

For TLs, PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD, taking as reference the smallest SD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame:
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PD (Assessed According to RECIST Version 1.1) or Death Due to Any Cause
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Percentage of Participants With PD (Assessed According to RECIST Version 1.1) or Death Due to Any Cause60.0 (58.1 to 85.4)
SecondaryProgression-free Survival (PFS) Assessed According to RECIST Version 1.1

PFS was defined as the time from start of treatment until first documented PD or death from any cause, whichever occurred first. Participants without PD, death, or who were lost to follow-up at the time of analysis were censored at the date of the last tumor assessment when non-progression was documented or at the last date of follow-up, whichever was last. Participants without tumor assessment data after the baseline were censored at baseline unless death occurred before first scheduled tumor assessment. PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, and/or unequivocal progression of existing non-TLs, or appearance of 1 or more new lesions. Median PFS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

Time frame:
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Reported as:
Median · months
Progression-free Survival (PFS) Assessed According to RECIST Version 1.1
monthsTrastuzumab, Pertuzumab, and Taxane
Progression-free Survival (PFS) Assessed According to RECIST Version 1.117.02 (12.48 to 31.18)
SecondaryPercentage of Participants Who Died Due to Any Cause

Percentage of participants who died due to any cause during the study was reported.

Time frame:
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died Due to Any Cause
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Percentage of Participants Who Died Due to Any Cause18.0 (58.1 to 85.4)
SecondaryOverall Survival (OS)

The OS was defined as the time from the start of treatment until death from any cause. Participants alive at the time of analysis and participants who were lost to follow-up were censored at their last clinical assessment date. Median OS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

Time frame:
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Reported as:
Median · months
Overall Survival (OS)
monthsTrastuzumab, Pertuzumab, and Taxane
Overall Survival (OS)NA (31.28 to NA)
SecondaryEvent-free Survival (EFS) Assessed According to RECIST Version 1.1

EFS was defined as the time from the start of treatment until the first documented initiation of non-protocol-specified treatment for metastatic breast cancer, PD, or death from any cause, whichever occurred first. Participants without treatment change, PD, death, or who were lost to follow-up at the time of analysis were censored at the date of the last tumor assessment when non-progression was documented or at the last date of follow-up, whichever was last. Participants without tumor assessment after baseline were censored at baseline unless death occurred before first scheduled tumor assessment. PD was defined as \>/=20% relative increase and \>/=5 mm of absolute increase in the SD of TLs, taking as reference the smallest SD recorded since treatment started, and/or unequivocal progression of existing non-TLs, or appearance of 1 or more new lesions. Median EFS was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

Time frame:
Baseline up to withdrawal of consent, loss to follow-up, disease progression, death, or study end (up to approximately 36 months)
Reported as:
Median · months
Event-free Survival (EFS) Assessed According to RECIST Version 1.1
monthsTrastuzumab, Pertuzumab, and Taxane
Event-free Survival (EFS) Assessed According to RECIST Version 1.117.02 (12.48 to 31.18)
SecondaryPercentage of Participants Who Died During Receiving Second-Line of Treatment

Percentage of participants who died from any cause during second-line of treatment was reported.

Time frame:
From start of second-line of treatment (any time from baseline up to 35 months) up to death due to any cause or study end (up to approximately 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Died During Receiving Second-Line of Treatment
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Percentage of Participants Who Died During Receiving Second-Line of Treatment30.0 (58.1 to 85.4)
SecondaryOS During Second-Line of Treatment

The OS during second-line therapy was defined as the time from the start of second-line therapy (failure of first-line therapy) until death from any cause. Participants alive at the time of analysis and participants who were lost to follow-up were censored at their last clinical assessment date. Median OS during second-line therapy was estimated using Kaplan-Meier method. The 95% CI was computed using Brookmeyer and Crowley method.

Time frame:
From start of second-line of treatment (any time from baseline up to 35 months) up to death due to any cause or study end (up to approximately 36 months)
Reported as:
Median · months
OS During Second-Line of Treatment
monthsTrastuzumab, Pertuzumab, and Taxane
OS During Second-Line of Treatment21.29 (14.85 to 29.04)
SecondaryNumber of Participants Receiving Second-Line Treatment by Treatment Type

Second-line anti-cancer treatment was initiated after disease progression on first-line therapy. Number of participants who started second-line of treatment by treatment type was reported. Participants who received combination treatment were counted for each treatment type.

Time frame:
Baseline up to approximately 35 months
Reported as:
Number · participants
Number of Participants Receiving Second-Line Treatment by Treatment Type
participantsTrastuzumab, Pertuzumab, and Taxane
Capecitabine8 (58.1 to 85.4)
Cyclophosphamide2
Denosumab2
Doxorubicin1
Epirubicin1
Eribulin1
Fluorouracil1
Lapatinib4
Nanoparticle Paclitaxel1
Paclitaxel4
Pertuzumab5
Trastuzumab13
Trastuzumab Emtansine10
Vinorelbine1
PrimaryPercentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Intensity of AEs were graded according to NCI CTCAE version 4.0 on a 5-point scale: Grade 1=Mild, intervention not indicated; Grade 2=Moderate, local or noninvasive intervention indicated; Grade 3=Severe or medically significant but not immediately life-threatening; Grade 4= Life-threatening consequences, urgent intervention indicated; and Grade 5=Death related to AE. Percentage of participants with AEs by maximum severity grades was reported.

Time frame:
Baseline up to 28 days after last study drug administration (up to 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With AEs by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0 Intensity Grades
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Grade 14.0 (92.9 to 100.0)
Grade 232.0 (39.3 to 68.2)
Grade 350.0
Grade 412.0
Grade 52.0
PrimaryPercentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Percentage of participants with AEs leading to premature discontinuation of IMPs (pertuzumab and trastuzumab) was reported. AEs included both SAEs and non-SAEs. The 95% CI was computed using Clopper-Pearson method.

Time frame:
Baseline up to 28 days after last study drug administration (up to 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Percentage of Participants With AEs Leading to Premature Discontinuation of Investigational Medicinal Products (IMPs)12.0 (4.5 to 24.3)
PrimaryPercentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA)

NYHA functional classification includes: Class I (no limitation in physical activity; ordinary physical activity does not cause fatigue, breathlessness or palpitation), Class II (slight limitation of physical activity; ordinary physical activity results in fatigue, palpitation, breathlessness or angina pectoris), Class III (marked limitation of physical activity; less than ordinary activity will lead to symptomatically 'moderate' heart failure) and Class IV (inability to carry out any physical activity without discomfort; symptoms of congestive cardiac failure are present even at rest). Percentage of participants with AEs suspected to be of cardiac origin by maximum NYHA classification was reported.

Time frame:
Baseline up to 28 days after last study drug administration (up to 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With AEs of Suspected Cardiac Origin, by New York Heart Association Classification (NYHA)
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Class I6.0 (4.5 to 24.3)
Class II4.0
Class III2.0
Class IV0.0
PrimaryPercentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%

LVEF was assessed using echocardiography (ECHO) or multiple-gated acquisition (MUGA) scans. Percentage of participants with LVEF below 50% at any time during the study was reported.

Time frame:
Baseline up to 28 days after last study drug administration (up to 36 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%
percentage of participantsTrastuzumab, Pertuzumab, and Taxane
Percentage of Participants With Left Ventricular Ejection Fraction (LVEF) Below 50%8.0

Adverse events

Collected over Baseline up to 28 days after last study drug administration (up to 36 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trastuzumab, Pertuzumab, and Taxane—27/50 (54%)49/50 (98%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventTrastuzumab, Pertuzumab, and Taxane
PyrexiaGeneral disorders7/50
Febrile neutropeniaBlood and lymphatic system disorders4/50
CellulitisInfections and infestations2/50
Upper respiratory tract infectionInfections and infestations2/50
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/50
AnaemiaBlood and lymphatic system disorders1/50
NeutropeniaBlood and lymphatic system disorders1/50
Cardiac failureCardiac disorders1/50
DiarrhoeaGastrointestinal disorders1/50
GastritisGastrointestinal disorders1/50
Most frequent other events
Showing 10 of 70
Most frequent other events
EventTrastuzumab, Pertuzumab, and Taxane
DiarrhoeaGastrointestinal disorders35/50
FatigueGeneral disorders34/50
Neuropathy peripheralNervous system disorders28/50
AlopeciaSkin and subcutaneous tissue disorders27/50
RashSkin and subcutaneous tissue disorders26/50
NauseaGastrointestinal disorders23/50
Upper respiratory tract infectionInfections and infestations19/50
MyalgiaMusculoskeletal and connective tissue disorders18/50
VomitingGastrointestinal disorders17/50
HeadacheNervous system disorders17/50

Baseline characteristics

Analysis was performed on the Intent-to-treat (ITT) population, which included all enrolled participants.

Age, Continuous
Age, Continuous(years)Trastuzumab, Pertuzumab, and Taxane
Mean52.9 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Trastuzumab, Pertuzumab, and Taxane
Female49
Male1
08

Study locations

13 sites
  • St George Hospital; Cancer Care Centre
    Kogarah, New South Wales 2217, Australia
  • Port Macquarie Base Hospital
    Port Macquarie, New South Wales 2444, Australia
  • Newcastle Mater Misericordiae Hospital; Oncology
    Waratah, New South Wales 2298, Australia
  • Mater Hospital; Cancer Services
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology
    Woolloongabba, Queensland 4102, Australia
  • Lyell McEwin Hospital
    Adelaide, South Australia 5112, Australia
  • Launceston General Hospital
    Launceston, Tasmania 7250, Australia
  • Bendigo Hospital; Oncology
    Bendigo, Victoria 3550, Australia
  • Monash Medical Centre; Oncology
    Clayton, Victoria 3168, Australia
  • Geelong Hospital; Andrew Love Cancer Centre
    Geelong, Victoria 3220, Australia
  • Royal Melbourne Hospital; Hematology and Medical Oncology
    Parkville, Victoria 3052, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • St John of God Murdoch Hospital; Oncology West
    Murdoch, Western Australia 6150, Australia
09

References and documents

Publications

  • Woodward N, De Boer RH, Redfern A, White M, Young J, Truman M, Beith J. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE). Clin Breast Cancer. 2019 Jun;19(3):216-224. doi: 10.1016/j.clbc.2019.02.008. Epub 2019 Feb 27. PubMed 30922805 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Nov 2016, 34 months.

Results were first posted in Jul 2018, 1 year 8 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 34 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2013
First posted
Dec 24, 2013
StartActual
Dec 5, 2013
Primary completionActual
Nov 4, 2016
CompletionActual
Nov 4, 2016
Results first posted
Jul 23, 2018
Last update
Sep 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02019277
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 24, 2013
Start date
Dec 5, 2013
Primary completion
Nov 4, 2016
Completion
Nov 4, 2016
Results posted
Jul 23, 2018
Last update
Sep 13, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion